Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC

Main Article Content

Jiping Zeng
Ken Batai
Benjamin Lee


nephrectomy; overall survival; renal cell carcinoma (RCC); surgical wait time (SWT)


In this study, we aimed to evaluate the impact of surgical wait time (SWT) on outcomes of patients with renal cell carcinoma (RCC), and to investigate risk factors associated with prolonged SWT. Using the National Cancer Database, we retrospectively reviewed the records of patients with pT3 RCC treated with radical or partial nephrectomy between 2004 and 2014. The cohort was divided based on SWT. The primary out-come was 5-year overall survival (OS). Logistic regression analysis was used to investigate the risk factors associated with delayed surgery. Cox proportional hazards models were fitted to assess relations between SWT and 5-year OS after adjusting for confounding factors. A total of 22,653 patients were included in the analysis. Patients with SWT > 10 weeks had higher occurrence of upstaging. Using logistic regression, we found that female patients, African-American or Spanish origin patients, treatment in academic or integrated network cancer center, lack of insurance, median household income of <$38,000, and the Charlson–Deyo score of ≥1 were more likely to have prolonged SWT. SWT > 10 weeks was associated with decreased 5-year OS (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.15–1.33). This risk was not markedly attenuated after adjusting for confounding variables, including age, gender, race, insurance status, Charlson–Deyo score, tumor size, and surgical margin status (adjusted HR, 1.13; 95% CI, 1.04–1.24). In conclusion, the vast majority of patients underwent surgery within 10 weeks. There is a statistically significant trend of increasing SWT over the study period. SWT > 10 weeks is associated with decreased 5-year OS.

Abstract 242 | PDF Downloads 103 XML Downloads 96 HTML Downloads 65


1. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69(1):7–34.
3. Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, et al. Wait times for cancer surgery in the United States: Trends and predictors of delays. Ann Surg. 2011;253(4):779–785.
4. Carr T, Teucher U, Mann J, Casson AG. Waiting for surgery from the patient perspective. Psychol Res Behav Manag. 2009;2:107–119.
5. Oudhoff JP, Timmermans DRM, Knol DL, Bijnen AB, van der Wal G. Waiting for elective general surgery: Impact on health related quality of life and psychosocial consequences. BMC Pub Health. 2007;7(19):164.
6. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: Systematic review of the literature. Eur Urol. 2006;50(6):1176–1182.
7. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong Y-N, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–339.
8. Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, et al. Using the National Cancer Database for outcomes research: A review. JAMA Oncol. 2017;3(12):1722–1728.
9. Merkow RP, Rademaker AW, Bilimoria KY. Practical guide to surgical data sets: National Cancer Database (NCDB). JAMA Surg. 2018;153(9):850–851.
10. Shinder BM, Farber NJ, Weiss RE, Jang TL, Kim IY, Singer EA, et al. Performing all major surgical procedures robotically will prolong wait times for surgery. Rob Surg (Auckland). 2017;4:87–91.
11. Canadian Surgical Wait Times (SWAT) Initiative. Consensus document: recommendations for optimal surgical wait times for patients with urological malignancies. Can J Urol. 2006;13(Suppl 3):62–64.
12. Lane BR, Tobert CM, Riedinger CB. Growth kinetics and active surveillance for small renal masses. Curr Opin Urol. 2012;22(5):353–359. 0b013e328355ecdf
13. Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang  A, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–529. juro.2017.04.100
14. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen  DY, Uzzo RG. The natural history of observed enhanc-ing renal masses: Meta-analysis and review of the world literature. J Urol. 2006;175(2):425–431. S0022-5347(05)00148-5
15. Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, et al. Contemporary management of small renal masses. Eur Urol. 2011;60(3):501–515.
16. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo  RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008;112(5):1051–1057.
17. Kim KH, You D, Jeong IG, Song C, Hong JH, Ahn H, et al. The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma. J Cancer Res Clin Oncol. 2012;138(9):1561– 1567.
18. Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith  JA, Jr., et al. Waiting time from initial urological con-sultation to nephrectomy for renal cell carcinoma—Does it affect survival? J Urol. 2008;179(6):2152–2157.
19. Martínez CH, Martin P, Chalasani V, Williams AK, Luke PPW, Izawa JI, et al. How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes? Can Urol Ass J. 2011;5(6):E148–E151.
20. Mano R, Vertosick EA, Hakimi AA, Sternberg IA, Sjoberg DD, Bernstein M, et al. The effect of delaying nephrectomy on onco-logic outcomes in patients with renal tumors greater than 4 cm. Urol Oncol. 2016;34(5):239.e1–e8.
21. Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20(6):1759–1765.
22. Mallin K, Browner A, Palis B, Gay G, McCabe R, Nogueira L, et al. Incident cases captured in the National Cancer Database compared with those in US population-based Central Cancer Registries in 2012–2014. Ann Surg Oncol. 2019;26(6):1604–1612.